Radionuclide Imaging in Renal Cell Carcinoma
- 1 January 2009
- book chapter
- Published by Springer Science and Business Media LLC
Abstract
No abstract availableThis publication has 47 references indexed in Scilit:
- Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal CancerClinical Cancer Research, 2005
- Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinomaClinical Nephrology, 2003
- F-18 Fluorodeoxyglucose Positron Emission Tomography in the Evaluation of Distant Metastases From Renal Cell CarcinomaJournal of Clinical Oncology, 2003
- Renal Cell Carcinoma With Retroperitoneal Lymph Nodes: Role of Lymph Node DissectionJournal of Urology, 2003
- Biodistribution and pharmacokinetics of 125I‐labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinomaInternational Journal of Cancer, 2003
- Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary reportZeitschrift für Krebsforschung und Klinische Onkologie, 2002
- The usefulness of F-18 deoxyglucose wholebody positron emission tomography (PET) for re-staging of renal cell cancerClinical Nephrology, 2002
- CLINICAL ROLE OF F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR DETECTION AND MANAGEMENT OF RENAL CELL CARCINOMAJournal of Urology, 2001
- Identification of the Target of Monoclonal Antibody A6H as Dipeptidyl Peptidase IV/CD26 by LC MSMSHybridoma, 2001
- Routine bone scan and serum alkaline phosphatase for staging in patients with renal cell carcinoma is not cost-effectiveEuropean Journal of Cancer, 1995